GILD
Gilead Sciences, Inc. Common Stock
$146.06
장중 · Vol 145.7K · 52주 $108.46–$157.29 · 기준 2026. 8. 21. PM 3:59 ET
일봉 $144.09 · Aug 31, 2026
GILD 가격 추세
종가
$144.09
시가
$144.23
고가
$145.00
저가
$143.25
30초 브리핑
GILD 오늘의 판단 요약
보유 데이터를 비교 가능한 문장으로 해석한 요약입니다.
52주 범위의 77%
52주 범위 중간 구간으로 가격 위치만으로 방향성은 제한적입니다.
Forward P/E 14.8배
업종 피어 비교 전에는 고평가·저평가를 단정하기 어렵습니다.
20일 평균의 1.1배
거래량은 최근 평균 범위입니다.
2026-10-29
실적 전후 변동성 확대 가능성이 있으므로 컨센서스 범위와 옵션 기대변동을 함께 보세요.
펀더멘털 기준 Sep 1, 2026 · 규칙 기반 요약이며 투자 조언이 아닙니다.
핵심 통계
GILD 일봉·펀더멘털 스냅샷 기준 주요 지표
펀더멘털 스냅샷 Sep 1, 2026
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
333 Lakeside Drive · Foster City, CA, United States · 직원 17,000명
시가총액
$181.46B
Trailing P/E
—
최근 12개월 이익 기준
Forward P/E
14.8
EPS (TTM)
$-2.66
배당 수익률
2.25%
배당성향
43.4%
베타
0.34
시장보다 방어적
ROE
-20.7%
P/B
15.35
EV/EBITDA
13.8
52주 범위
$108.46 – $157.29
현재 위치 77%
거래량
5.38M
20일 평균 4.77M · 1.1배
애널리스트 의견
매수 75%
총 28명 · 0m
DITM LEAPS Analysis
GILD 장기 DITM 콜옵션을 진입 적합도 순으로 비교
| Contract | Expiry | Strike | Price | Lev. | Delta | Extrinsic | Spread | IV | OI | Score | 상세 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GILD271217C00090000 | 12/17/27 · 1.3Y | $90.00 | $59.50 | 2.2x | 0.9078 | 5.3% | 6.72% | 44.59% | 72 | 86.45 | |
| GILD271217C00092500 | 12/17/27 · 1.3Y | $92.50 | $57.25 | 2.3x | 0.8996 | 6.0% | 7.86% | 44.22% | 63 | 84.92 | |
| GILD280121C00090000 | 1/21/28 · 1.4Y | $90.00 | $59.75 | 2.2x | 0.9046 | 5.7% | 7.53% | 44.51% | 28 | 84.79 | |
| GILD271217C00095000 | 12/17/27 · 1.3Y | $95.00 | $55.00 | 2.4x | 0.8913 | 6.7% | 9.09% | 43.78% | 80 | 83.72 | |
| GILD280121C00095000 | 1/21/28 · 1.4Y | $95.00 | $55.50 | 2.3x | 0.8887 | 7.5% | 9.01% | 43.58% | 65 | 82.94 | |
| GILD280121C00100000 | 1/21/28 · 1.4Y | $100.00 | $51.65 | 2.5x | 0.8761 | 10.3% | 7.16% | 41.19% | 145 | 82.24 | |
| GILD271217C00100000 | 12/17/27 · 1.3Y | $100.00 | $51.25 | 2.5x | 0.8743 | 9.6% | 8.78% | 42.69% | 247 | 82.08 | |
| GILD271217C00097500 | 12/17/27 · 1.3Y | $97.50 | $53.25 | 2.4x | 0.8829 | 8.3% | 8.45% | 43.27% | 11 | 80.41 | |
| GILD271217C00105000 | 12/17/27 · 1.3Y | $105.00 | $47.25 | 2.6x | 0.8564 | 12.5% | 9.52% | 41.39% | 62 | 77.65 | |
| GILD280121C00105000 | 1/21/28 · 1.4Y | $105.00 | $47.50 | 2.6x | 0.8548 | 13.0% | 10.53% | 41.06% | 80 | 77.35 | |
| GILD271217C00110000 | 12/17/27 · 1.3Y | $110.00 | $43.77 | 2.8x | 0.8375 | 17.0% | 7.88% | 39.91% | 40 | 74.12 | |
| GILD280121C00110000 | 1/21/28 · 1.4Y | $110.00 | $43.75 | 2.8x | 0.8364 | 16.9% | 10.29% | 39.55% | 65 | 73.95 | |
| GILD270917C00110000 | 9/17/27 · 1.0Y | $110.00 | $42.00 | 2.9x | 0.8430 | 13.5% | 9.52% | 40.73% | 1 | 71.89 | |
| GILD271217C00115000 | 12/17/27 · 1.3Y | $115.00 | $39.18 | 3.1x | 0.8218 | 20.0% | 8.55% | 36.95% | 39 | 71.84 | |
| GILD280121C00115000 | 1/21/28 · 1.4Y | $115.00 | $39.93 | 3.0x | 0.8176 | 21.5% | 9.64% | 37.61% | 42 | 70.32 | |
| GILD280121C00120000 | 1/21/28 · 1.4Y | $120.00 | $36.75 | 3.1x | 0.7902 | 28.3% | 12.24% | 37.95% | 1,185 | 67.07 | |
| GILD271217C00120000 | 12/17/27 · 1.3Y | $120.00 | $36.30 | 3.2x | 0.7899 | 27.4% | 12.12% | 38.39% | 75 | 64.59 | |
| GILD271217C00125000 | 12/17/27 · 1.3Y | $125.00 | $32.32 | 3.5x | 0.7704 | 34.0% | 9.13% | 35.12% | 82 | 61.71 | |
| GILD270917C00125000 | 9/17/27 · 1.0Y | $125.00 | $30.38 | 3.7x | 0.7738 | 29.7% | 9.05% | 34.96% | 1 | 59.71 | |
| GILD280121C00125000 | 1/21/28 · 1.4Y | $125.00 | $33.98 | 3.3x | 0.7655 | 37.2% | 8.98% | 36.82% | 63 | 58.98 |
재무제표
GILD 연간 손익·현금흐름·재무상태
매출 성장률
+2.4%
최근 연간 YoY
EPS 성장률
+1684.2%
최근 연간 YoY
영업이익률
39.7%
최근 연간
FCF 마진
32.1%
잉여현금흐름 / 매출
매출 추세
순이익 추세
잉여현금흐름 추세
| 항목 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| 매출 | $29.44B+2.4% | $28.75B+6.0% | $27.12B-0.6% | $27.28B |
| 매출총이익 | $23.21B+3.1% | $22.50B+9.1% | $20.62B-4.7% | $21.62B |
| 영업이익 | $11.70B+10.4% | $10.60B+19.9% | $8.84B-19.5% | $10.97B |
| 순이익 | $8.51B+1672.9% | $480.00M-91.5% | $5.67B+23.4% | $4.59B |
| 희석 EPS | $6.78+1684.2% | $0.38-91.6% | $4.50+23.6% | $3.64 |
| EBITDA | $13.58B+206.3% | $4.43B-57.8% | $10.50B+18.6% | $8.85B |
| 영업현금흐름 | $10.02B-7.5% | $10.83B+35.2% | $8.01B-11.8% | $9.07B |
| 잉여현금흐름 | $9.46B-8.2% | $10.30B+38.9% | $7.42B-11.1% | $8.34B |
| 총자산 | $59.02B+0.0% | $58.99B-5.0% | $62.13B-1.7% | $63.17B |
| 총부채 | $24.94B-6.6% | $26.71B+6.9% | $24.99B-1.0% | $25.23B |
최신 연도 우선 · 작은 퍼센트는 직전 연도 대비 변화입니다.
캘린더
GILD 실적·배당 일정
매출 하단
$7.52B
EPS 하단
$1.90
매출 상단
$8.08B
배당 지급일
2026-09-29
D-28
실적 발표일
2026-10-29
D-58
EPS 상단
$2.68
매출 컨센서스
$7.78B
EPS 컨센서스
$2.15
배당락일
2026-09-15
D-14
최근 배당
| 배당락일 | 주당 배당 |
|---|---|
| Jun 15, 2026 | $0.8200 |
| Mar 13, 2026 | $0.8200 |
| Dec 15, 2025 | $0.7900 |
| Sep 15, 2025 | $0.7900 |
| Jun 13, 2025 | $0.7900 |
| Mar 14, 2025 | $0.7900 |
| Dec 13, 2024 | $0.7700 |
| Sep 13, 2024 | $0.7700 |
뉴스
GILD 관련 최신 기사
- 일반
Cocrystal Pharma: The Strategic Reset Investors May Be Missing
By Mike Sheikh Cocrystal Pharma (NASDAQ: COCP) may look like another undercapitalized, clinical-stage biotech searching for its niche, and in need of a rescue, but there is more to this story than what meets the eye. Investors glancing at the stock chart may miss the signs of a strategic reset orchestrated by biotech legends, and miss […] The post Cocrystal Pharma: The Strategic Reset Investors May Be Missing appeared first on ExecEdge.
Exec Edge · Aug 31, 2026
제품·기술3 Unpopular Stocks with Open Questions
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
StockStory · Aug 31, 2026
규제·법률Gilead Wins FDA Nod for Bixlenvo in Adults Living With HIV Infection
GILD wins FDA approval for Bixlenvo, a once-daily HIV regimen offering a smaller single-tablet option for patients on complex therapies.
Zacks · Aug 28, 2026
- 규제·법률
Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines
Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after study data were “inadvertently” published ahead of a medical meeting.
BioPharma Dive · Aug 28, 2026
제품·기술Gilead (GILD) Stock Looks Undervalued After A 147% Five Year Run
Gilead Sciences has delivered strong share price gains over the past five years, yet based on broad valuation checks it still screens as inexpensive relative to its fundamentals. For investors, the stock now sits in an interesting spot where a powerful HIV and oncology franchise is reflected in the price to some extent, but the broader valuation read still points to room for a more optimistic view than the market currently implies. Over the past 5 years, Gilead Sciences has returned about...
Simply Wall St. · Aug 27, 2026
- 제품·기술
Gilead Sciences (GILD) Wins EU Trodelvy Approval, Is The Stock Fully Priced?
Gilead Sciences (GILD) is back in focus after the European Commission approved Trodelvy plus Keytruda for certain first line metastatic triple negative breast cancer patients, expanding the company’s oncology franchise in Europe. For investors tracking the bigger picture, Gilead Sciences’ 1 month share price return of 10.25% and year to date share price return of 21.78% point to firming momentum. The 1 year total shareholder return of 34.99% and 5 year total shareholder return of 145.70%...
Simply Wall St. · Aug 27, 2026
- 제품·기술
What Does Gilead Sciences (GILD) Gain From Its Expanded EU Breast Cancer Approval?
Gilead Sciences (NasdaqGS:GILD) received expanded European Commission approval for Trodelvy in combination with Keytruda as a first-line treatment for metastatic triple-negative breast cancer across PD-L1 status in Europe. The decision establishes Trodelvy plus Keytruda as the first antibody-drug conjugate and immunotherapy combination approved for first-line metastatic TNBC across the European Union. The ruling broadens Trodelvy’s addressable patient population in Europe and further...
Simply Wall St. · Aug 27, 2026
실적Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy Lifting
Since earnings, investors have focused mainly on the biotech company's growth potential with its HIV PrEP medicines.
Motley Fool · Aug 26, 2026
제품·기술Vivace Therapeutics names new CEO as it prepares Phase 3 trial for mesothelioma drug
Vivace Therapeutics has appointed Craig Gibbs as President and CEO as the company prepares to advance its lead candidate, VT3989, into a pivotal Phase 3 registrational trial. The clinical-stage biopharmaceutical company also named Ellen Lubman as Chief Business and Strategy Officer and...
Proactive · Aug 26, 2026
- 일반
Eli Lilly Is Pulling Away From the Rest of Healthcare
Its growth profile stands well above major sector peers.
GuruFocus.com · Aug 25, 2026
홀더
GILD 내부자·기관 보유 현황
최신 보고 목록 기준이며 실제 거래 시점과 보고일 사이에는 시차가 있습니다.
기관 보유
92.3%
기관 보유 (유동주식)
92.4%
내부자 보유
0.1%
기관 수
3,076
주요 기관 홀더
| 홀더 | 주식 수 | 평가액 | 지분 | 변동 | 보고일 |
|---|---|---|---|---|---|
| Blackrock Inc. | 121.84M | $17.83B | 9.8% | 2.4% | Jun 30, 2026 |
| Vanguard Capital Management LLC | 81.09M | $11.87B | 6.5% | 0.5% | Jun 30, 2026 |
| FMR, LLC | 66.87M | $9.79B | 5.4% | -7.0% | Jun 30, 2026 |
| State Street Corporation | 61.22M | $8.96B | 4.9% | 2.3% | Jun 30, 2026 |
| Capital World Investors | 40.99M | $6.00B | 3.3% | -0.7% | Jun 30, 2026 |
| Invesco Ltd. | 39.82M | $5.83B | 3.2% | -4.2% | Jun 30, 2026 |
| Vanguard Portfolio Management LLC | 35.32M | $5.17B | 2.8% | 0.5% | Jun 30, 2026 |
| Geode Capital Management, LLC | 30.07M | $4.40B | 2.4% | 1.1% | Jun 30, 2026 |
| Price (T.Rowe) Associates Inc | 30.00M | $4.39B | 2.4% | 14.3% | Jun 30, 2026 |
| Morgan Stanley | 24.00M | $3.51B | 1.9% | 3.0% | Jun 30, 2026 |
면책조항: 증시가격은 모든 주식 시장의 최신 증시가격을 표시하는 것은 아니며, 정보가 지연되거나 잘못될 수 있습니다. 거래 목적이나 조언이 아닌 정보 제공 목적으로만 제공됩니다.